Micurx Pharmaceuticals Inc., of Hayward, Calif., said it started a Phase II trial testing lead compound MRX-I, an oxazolidinone antibiotic, for treating gram-positive infections, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.